Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Repair of infarcted myocardium by skeletal muscle-derived mesenchymal stromal cells delivered by a bioprinted collagen patch.

Guesdon R., Santoro S., Cras A., Pagin E., Serteyn D., Ceusters J.

Animal Study on Cardiovascular Disease, Chronic Inflammation, Immune Modulation, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40764930
DOI
10.1186/s13287-025-04552-7

Abstract (original English)

Mesenchymal stromal cells (MSC) are commonly investigated for post-infarction cardiac repair because of their angiogenic, anti-inflammatory and immunomodulatory properties. However, autologous sources (bone marrow and adipose tissue) require substantially invasive harvest procedures while allogeneic MSC from the cord raise the issue of batch to batch variability. This study assessed the effects of another under-investigated cell source: the skeletal muscle whose autologous MSC feature the clinically appealing advantage of being retrievable by a minimally invasive microbiopsy. MSC differentiated from induced pluripotent stem cells (iPSC) were selected as controls as they also look clinically attractive because of their high scalability and high degree of reproducibility. In vitro, muscle-derived (md) MSC exhibited typical MSC features including a tri-lineage differentiation potential and had robust angiogenic, anti-inflammatory, anti-fibrotic and immune-modulatory effects. Overall, they outperformed iPSC-MSC which raised a safety concern linked to the persistence of some pluripotency-associated markers. They were thus chosen for the subsequent in vivo evaluation in a rat model of left ventricular (LV) dysfunction induced by ischemia/reperfusion. To this end, mdMSC were embedded in a collagen bioprinted gel; the resulting epicardially-delivered patch significantly improved LV eje

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsMyocardial InfarctionAnimalsMesenchymal Stem Cell TransplantationRatsCollagenCell DifferentiationMuscle, SkeletalInduced Pluripotent Stem CellsMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research